Skip to content

Study · Randomized controlled trial · 2001

4 results

A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.

Takeuchi S, Minoura H, Shibahara T, Tsuiki Y, Noritaka F, Toyoda N

Fertility and sterility1 Sept 2001Cited by 5 (Europe PMC)

PMID11532477 (opens in a new tab)DOI10.1016/s0015-0282(01)01977-x (opens in a new tab)PepBankPUB-11532477
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In long-protocol IVF, nafarelin and buserelin did not differ significantly in hormone concentrations on hCG administration, gonadotropin dosage, retrieved oocytes, transferred embryos or pregnancy rates.

    In plain wordsIn long-protocol IVF, measured treatment outcomes were similar with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    No significant changeLong IVF protocol outcomes
    Study

    n: not reported in source

    Comparator
    Buserelin acetate 300 microg three times daily
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 microg twice daily for 7 days, then 200 microg dailyAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in baseline concentrations of E(2) and FSH, concentrations of E(2), P4, FSH, LH on hCG administration, gonadotropin dosage, the number of oocytes retrieved and embryos transferred, or pregnancy rates between groups 1 and 2, groups 3 and 4, groups 5…
    2 context sentences
    Summary · context
    To compare the efficacy of a draw-back nafarelin acetate protocol with routine buserelin acetate administration for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
    Summary · context
    Patients were randomized to receive either full-dose nafarelin acetate (200 microg b.i.d.) treatment for 7 days followed by half-dose nafarelin acetate (200 microg daily) or buserelin acetate (300 microg t.i.d.).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In short-protocol IVF, nafarelin and buserelin did not differ significantly in hormone concentrations on hCG administration, gonadotropin dosage, retrieved oocytes, transferred embryos or pregnancy rates.

    In plain wordsIn short-protocol IVF, measured treatment outcomes were similar with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    No significant changeShort IVF protocol outcomes
    Study

    n: not reported in source

    Comparator
    Buserelin acetate 300 microg three times daily
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 microg twice daily for 7 days, then 200 microg dailyAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in baseline concentrations of E(2) and FSH, concentrations of E(2), P4, FSH, LH on hCG administration, gonadotropin dosage, the number of oocytes retrieved and embryos transferred, or pregnancy rates between groups 1 and 2, groups 3 and 4, groups 5…
    2 context sentences
    Summary · context
    To compare the efficacy of a draw-back nafarelin acetate protocol with routine buserelin acetate administration for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
    Summary · context
    Patients were randomized to receive either full-dose nafarelin acetate (200 microg b.i.d.) treatment for 7 days followed by half-dose nafarelin acetate (200 microg daily) or buserelin acetate (300 microg t.i.d.).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In long-protocol ICSI, nafarelin and buserelin did not differ significantly in hormone concentrations on hCG administration, gonadotropin dosage, retrieved oocytes, transferred embryos or pregnancy rates.

    In plain wordsIn long-protocol ICSI, measured treatment outcomes were similar with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    No significant changeLong ICSI protocol outcomes
    Study

    n: not reported in source

    Comparator
    Buserelin acetate 300 microg three times daily
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 microg twice daily for 7 days, then 200 microg dailyAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in baseline concentrations of E(2) and FSH, concentrations of E(2), P4, FSH, LH on hCG administration, gonadotropin dosage, the number of oocytes retrieved and embryos transferred, or pregnancy rates between groups 1 and 2, groups 3 and 4, groups 5…
    2 context sentences
    Summary · context
    To compare the efficacy of a draw-back nafarelin acetate protocol with routine buserelin acetate administration for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
    Summary · context
    Patients were randomized to receive either full-dose nafarelin acetate (200 microg b.i.d.) treatment for 7 days followed by half-dose nafarelin acetate (200 microg daily) or buserelin acetate (300 microg t.i.d.).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In short-protocol ICSI, nafarelin and buserelin did not differ significantly in hormone concentrations on hCG administration, gonadotropin dosage, retrieved oocytes, transferred embryos or pregnancy rates.

    In plain wordsIn short-protocol ICSI, measured treatment outcomes were similar with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    No significant changeShort ICSI protocol outcomes
    Study

    n: not reported in source

    Comparator
    Buserelin acetate 300 microg three times daily
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    200 microg twice daily for 7 days, then 200 microg dailyAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant differences in baseline concentrations of E(2) and FSH, concentrations of E(2), P4, FSH, LH on hCG administration, gonadotropin dosage, the number of oocytes retrieved and embryos transferred, or pregnancy rates between groups 1 and 2, groups 3 and 4, groups 5…
    2 context sentences
    Summary · context
    To compare the efficacy of a draw-back nafarelin acetate protocol with routine buserelin acetate administration for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).
    Summary · context
    Patients were randomized to receive either full-dose nafarelin acetate (200 microg b.i.d.) treatment for 7 days followed by half-dose nafarelin acetate (200 microg daily) or buserelin acetate (300 microg t.i.d.).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.